Apricus Biosciences, Inc. (NASDAQ:APRI) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
press release announcing its results of operations for the three
months ended March 31, 2017. The full text of such press release
is furnished as Exhibit 99.1 to this report.
information in this Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof,
except as expressly set forth by specific reference in such
filing to this Item 2.02 of this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated May 11, 2017
|
About Apricus Biosciences, Inc. (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe. Apricus Biosciences, Inc. (NASDAQ:APRI) Recent Trading Information
Apricus Biosciences, Inc. (NASDAQ:APRI) closed its last trading session up +0.09 at 1.27 with 472,204 shares trading hands.
